Do analysts prefer VLG or STX?

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venture Life Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to VLG or STX?

In the previous week, Shield Therapeutics had 1 more articles in the media than Venture Life Group. MarketBeat recorded 2 mentions for Shield Therapeutics and 1 mentions for Venture Life Group. Venture Life Group's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.19 indicating that Venture Life Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Venture Life Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shield Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BVXP or STX?

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate ORPH or STX?

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Open Orphan. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Open Orphan 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better valuation and earnings, ORPH or STX?

Open Orphan has higher earnings, but lower revenue than Shield Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Open Orphan £34.71M 0.00 N/A N/A N/A Shield Therapeutics £58.63M 0.90 -£36.28M -£2.00 N/A

Shield Therapeutics (STX) Competitors

GBX 4.91 +0.01 (+0.20%)

As of 08/21/2026 12:13 PM Eastern

Compare

STX vs. VLG, BVXP, ORPH, EAH, and MRK

Should you buy Shield Therapeutics stock or one of its competitors? Shield Therapeutics's main competitors and comparable companies include Venture Life Group (VLG), Bioventix (BVXP), Open Orphan (ORPH), ECO Animal Health Group (EAH), and Marks Electrical Group (MRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Shield Therapeutics compare to Venture Life Group?

Venture Life Group (LON:VLG) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Venture Life Group has a net margin of 17.42% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Venture Life Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venture Life Group	17.42%	7.82%	1.56%
Shield Therapeutics	-17.76%	64.57%	-47.85%

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venture Life Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Shield Therapeutics had 1 more articles in the media than Venture Life Group. MarketBeat recorded 2 mentions for Shield Therapeutics and 1 mentions for Venture Life Group. Venture Life Group's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.19 indicating that Venture Life Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Venture Life Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shield Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Venture Life Group has a beta of 0.217, meaning that its share price is 78% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.717, meaning that its share price is 72% more volatile than the broader market.

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Venture Life Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venture Life Group	£35.17M	2.29	£747.21K	£4.37	15.26
Shield Therapeutics	£58.63M	0.90	-£36.28M	-£2.00	N/A

Summary

Venture Life Group beats Shield Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Shield Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Bioventix has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.35	£8.12M	£140.52	12.55
Shield Therapeutics	£58.63M	0.90	-£36.28M	-£2.00	N/A

Bioventix has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.717, meaning that its stock price is 72% more volatile than the broader market.

Bioventix has a net margin of 59.30% compared to Shield Therapeutics' net margin of -17.76%. Bioventix's return on equity of 65.83% beat Shield Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Shield Therapeutics	-17.76%	64.57%	-47.85%

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Shield Therapeutics had 2 more articles in the media than Bioventix. MarketBeat recorded 2 mentions for Shield Therapeutics and 0 mentions for Bioventix. Bioventix's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.19 indicating that Bioventix is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventix	Neutral
Shield Therapeutics	Neutral

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Bioventix beats Shield Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Shield Therapeutics compare to Open Orphan?

Open Orphan (LON:ORPH) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Open Orphan has higher earnings, but lower revenue than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
Shield Therapeutics	£58.63M	0.90	-£36.28M	-£2.00	N/A

Open Orphan has a net margin of 0.00% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Open Orphan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
Shield Therapeutics	-17.76%	64.57%	-47.85%

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Open Orphan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Open Orphan	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Shield Therapeutics had 2 more articles in the media than Open Orphan. MarketBeat recorded 2 mentions for Shield Therapeutics and 0 mentions for Open Orphan. Open Orphan's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.19 indicating that Open Orphan is being referred to more favorably in the media.

Company	Overall Sentiment
Open Orphan	Neutral
Shield Therapeutics	Neutral

Summary

Shield Therapeutics beats Open Orphan on 9 of the 12 factors compared between the two stocks.

How does Shield Therapeutics compare to ECO Animal Health Group?

Shield Therapeutics (LON:STX) and ECO Animal Health Group (LON:EAH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

6.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 40.8% of ECO Animal Health Group shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Comparatively, 11.3% of ECO Animal Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Shield Therapeutics presently has a consensus price target of GBX 15, suggesting a potential upside of 205.50%. ECO Animal Health Group has a consensus price target of GBX 160, suggesting a potential upside of 59.36%. Given Shield Therapeutics' higher probable upside, research analysts clearly believe Shield Therapeutics is more favorable than ECO Animal Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ECO Animal Health Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Shield Therapeutics has a beta of 1.717, indicating that its share price is 72% more volatile than the broader market. Comparatively, ECO Animal Health Group has a beta of 0.71863484, indicating that its share price is 28% less volatile than the broader market.

ECO Animal Health Group has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£58.63M	0.90	-£36.28M	-£2.00	N/A
ECO Animal Health Group	£87.53M	0.77	£1.05M	£3.15	31.87

ECO Animal Health Group has a net margin of 2.50% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat ECO Animal Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-17.76%	64.57%	-47.85%
ECO Animal Health Group	2.50%	2.55%	2.14%

In the previous week, Shield Therapeutics had 2 more articles in the media than ECO Animal Health Group. MarketBeat recorded 2 mentions for Shield Therapeutics and 0 mentions for ECO Animal Health Group. ECO Animal Health Group's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.19 indicating that ECO Animal Health Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Shield Therapeutics	Neutral
ECO Animal Health Group	Neutral

Summary

ECO Animal Health Group beats Shield Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Shield Therapeutics compare to Marks Electrical Group?

Marks Electrical Group (LON:MRK) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Marks Electrical Group presently has a consensus target price of GBX 52.50, indicating a potential upside of 15.51%. Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 205.50%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Shield Therapeutics is more favorable than Marks Electrical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marks Electrical Group	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Shield Therapeutics had 2 more articles in the media than Marks Electrical Group. MarketBeat recorded 2 mentions for Shield Therapeutics and 0 mentions for Marks Electrical Group. Marks Electrical Group's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.19 indicating that Marks Electrical Group is being referred to more favorably in the media.

Company	Overall Sentiment
Marks Electrical Group	Neutral
Shield Therapeutics	Neutral

0.2% of Marks Electrical Group shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 75.4% of Marks Electrical Group shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Marks Electrical Group has higher revenue and earnings than Shield Therapeutics. Marks Electrical Group is trading at a lower price-to-earnings ratio than Shield Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marks Electrical Group	£107.93M	0.44	£426.93K	-£0.40	N/A
Shield Therapeutics	£58.63M	0.90	-£36.28M	-£2.00	N/A

Marks Electrical Group has a beta of 0.577, indicating that its share price is 42% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.717, indicating that its share price is 72% more volatile than the broader market.

Marks Electrical Group has a net margin of -0.39% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Marks Electrical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marks Electrical Group	-0.39%	-4.18%	0.91%
Shield Therapeutics	-17.76%	64.57%	-47.85%

Summary

Shield Therapeutics beats Marks Electrical Group on 8 of the 15 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STX vs. The Competition

Export

Metric	Shield Therapeutics	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£51.89M	£12.60B	£7.38B	£2.54B
Dividend Yield	N/A	2.61%	2.53%	6.17%
P/E Ratio	-2.46	789.80	272.60	367.57
Price / Sales	0.90	759.74	623.33	83,481.74
Price / Cash	6.36	96.77	78.62	27.89
Price / Book	89.72	11.89	13.05	7.19
Net Income	-£36.28M	£2.81B	£3.47B	£5.89B
7 Day Performance	14.75%	1.77%	2.09%	0.30%
1 Month Performance	-20.81%	3.85%	6.64%	3.31%
1 Year Performance	-40.48%	6.56%	25.02%	22.13%

Shield Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STX Shield Therapeutics	1.5345 of 5 stars	GBX 4.91 +0.2%	GBX 15 +205.5%	-40.5%	£51.89M	£58.63M	N/A	40,000	News Coverage Gap Down
VLG Venture Life Group	N/A	GBX 67.75 -0.4%	N/A	+15.2%	£81.92M	£35.17M	15.50	165	News Coverage
BVXP Bioventix	N/A	GBX 1,538 +2.5%	N/A	-29.4%	£80.36M	£12.54M	10.95	12
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
EAH ECO Animal Health Group	N/A	GBX 100.15 -2.3%	GBX 160 +59.8%	+37.0%	£66.82M	£87.53M	31.79	234	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:STX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shield Therapeutics (STX) Competitors

STX vs. VLG, BVXP, ORPH, EAH, and MRK

How does Shield Therapeutics compare to Venture Life Group?

Summary

How does Shield Therapeutics compare to Bioventix?

Summary

How does Shield Therapeutics compare to Open Orphan?

Summary

How does Shield Therapeutics compare to ECO Animal Health Group?

Summary

How does Shield Therapeutics compare to Marks Electrical Group?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shield Therapeutics (STX) Competitors

STX vs. VLG, BVXP, ORPH, EAH, and MRK

How does Shield Therapeutics compare to Venture Life Group?

Is VLG or STX more profitable?

Do analysts prefer VLG or STX?

Does the media refer more to VLG or STX?

Which has more risk & volatility, VLG or STX?

Do insiders & institutionals hold more shares of VLG or STX?

Which has better earnings and valuation, VLG or STX?

Summary

How does Shield Therapeutics compare to Bioventix?

Which has stronger valuation and earnings, BVXP or STX?

Which has more volatility & risk, BVXP or STX?

Is BVXP or STX more profitable?

Do analysts prefer BVXP or STX?

Does the media favor BVXP or STX?

Do insiders and institutionals believe in BVXP or STX?

Summary

How does Shield Therapeutics compare to Open Orphan?

Which has better valuation and earnings, ORPH or STX?

Is ORPH or STX more profitable?

Do analysts rate ORPH or STX?

Do insiders & institutionals hold more shares of ORPH or STX?

Does the media favor ORPH or STX?

Summary

How does Shield Therapeutics compare to ECO Animal Health Group?

Do institutionals & insiders believe in STX or EAH?

Do analysts rate STX or EAH?

Which has more risk and volatility, STX or EAH?

Which has better earnings and valuation, STX or EAH?

Is STX or EAH more profitable?

Does the media prefer STX or EAH?

Summary

How does Shield Therapeutics compare to Marks Electrical Group?

Do analysts recommend MRK or STX?

Does the media favor MRK or STX?

Do insiders & institutionals believe in MRK or STX?

Which has preferable earnings and valuation, MRK or STX?

Which has more volatility & risk, MRK or STX?

Is MRK or STX more profitable?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools